


21ST EDITION

# Remington

The Science and Practice of Pharmacy





Editor: David B. Troy Managing Editor: Matthew J. Hauber Marketing Manager: Marisa A. O'Brien

Lippincott Williams & Wilkins

351 West Camden Street Baltimore, Maryland 21201-2436 USA

530 Walnut Street

Philadelphia, PA 19100

All rights reserved. This book is protected by copyright. No part of this book may be reproduced in any form or by any means, all rights reserved. This book is protected by copyright. No part of this book may be reproduced in any form or by any means, all rights reserved. This book is protected by copyright. All rights reserved. This book is protected by copyright. No part of this book is protected by copyright. right owner.

The publisher is not responsible (as a matter of product liability, negligence or otherwise) for any injury resulting from any The publisher is not responsible (as a matter of product liability, negligible). The publisher is not responsible (as a matter of product liability, negligible) and any material contained herein. This publication contains information relating to general principles of medical care which should not material contained herein. This publication contains any material contained herein. material contained herein. This publication contains information relatively product information and package inserts should not be construed as specific instructions for individual patients. Manufacturer's product information and package inserts should be reviewed for current information, including contraindications, dosages and precautions.

Printed in the United States of America

Entered according to Act of Congress, in the year 1885 by Joseph P Remington, in the Office of the Librarian of Congress, at Washington DC

Copyright 1889, 1894, 1905, 1907, 1917, by Joseph P Remington

Copyright 1926, 1936, by the Joseph P Remington Estate

Copyright 1948, 1951, by the Philadelphia College of Pharmacy and Science

Copyright 1956, 1960, 1965, 1970, 1975, 1980, 1985, 1990, 1995, by the Philadelphia College of Pharmacy and Science

Copyright 2000, 2006, by the University of the Sciences in Philadelphia

All Rights Reserved Library of Congress Catalog Card Information is available ISBN 0-7817-4673-6

The publishers have made every effort to trace the copyright holders for borrowed material. If they have inadvertently overlooked any, they will be pleased to make the necessary arrangements at the first opportunity.

The use of structural formulas from USAN and the USP Dictionary of Drug Names is by permission of The USP Convention. The

Notice—This text is not intended to represent, nor shall it be interpreted to be, the equivalent of or a substitute for the official United States Pharmacopeia (USP) and/or the National Formula (USP). United States Pharmacopeia (USP) and/or the National Formulary (NF). In the equivalent of or a substitute for the official USP or NF standards of strength, quality purity problem. current official USP or NF standards of strength, quality, purity, packaging and labeling for drugs and representations of them herein, the context and effect of the official compendia shall properly

To purchase additional copies of this book call our customer service department at (800) 638-3030 or fax orders to (301) 714,2224



# Contents

Pa	rt 1 Orientation	49	Biotechnology and Drugs
1		50	Aerosols
2		51	Quality Assurance and Control
3		52	Bioavailability and Bioequivalency Testing
4		53	Plastic Packaging Materials
5	그리고 그 그 사람이 되는데 이렇게 하면서 이렇게 되었다면서 하는데 하는데 그는데 그리고 하는데 그리고 되었다. 그 없다.	54	Pharmaceutical Necessities
6		55	
7	Pharmacists and Public Health	Part 6	Pharmacokinetics and Pharmacodynamics
8	Information Resources in Pharmacy and the Pharmaceutical Sciences	56	Diseases: Manifestations and Pathophysiology 1095
	Clinical Drug Literature	57	Drug Absorption, Action, and Disposition
9	Research	58	Basic Pharmacokinetics and Pharmacodynamics1171
10	Research	59	Clinical Pharmacokinetics and Pharmacodynamics 1191
Part	2 Pharmaceutics	60	Priniciples of Immunology
11	Metrology and Pharmaceutical Calculations99	61	Pharmacogenomics
12	Statistics	62	Pharmacokinetics/Pharmacodynamics in
13	Molecular Structure, Properties, and States of Matter 162	63	Drug Development
14	Complex Formation		
15	Thermodynamics	Part 7	Pharmaceutical and Medicinal Agents
16	Solutions and Phase Equilibria	64	Diagnostic Drugs and Reagents
17	Ionic Solutions and Electrolytic Equilibria	65	Topical Drugs
18	Tonicity, Osmoticity, Osmolality, and Osmolarity	66	Gastrointestinal and Liver Drugs
19	Chemical Kinetics	67	Blood, Fluids, Electrolytes, and Hematological Drugs 1318
20	Interfacial Phenomena	68	Cardiovascular Drugs
21	Colloidal Dispersions	69	Respiratory Drugs
22	Coarse Dispersions	70	Sympathomimetic Drugs
23	Rheology	71	Cholinomimetic Drugs
23	Micology	72	Adrenergic Antagonists and Adrenergic
Part 3	3 Pharmaceutical Chemistry	12	Neuron Blocking Drugs
	Inorganic Pharmaceutical Chemistry	73	Antimuscarinic and Antispasmodic Drugs
24	Oceanic Pharmaceutical Chemistry 386	74	Skeletal Muscle Relaxants
25	Organic Pharmaceutical Chemistry	75	Diuretic Drugs
26	Drug Nomenclature—United States Adopted Names	76	Uterine and Antimigraine Drugs
27	Structure-Activity Relationship and Drug Design	77	Hormones and Hormone Antagonists
28	Fundamentals of Medical Radionuclides	78	General Anesthetics
29	Fundamentals of Medical Radionacides	79	Local Anesthetics
art 4	Pharmaceutical Testing, Analysis, and Control	80	Antianxiety Agents and Hypnotic Drugs1486
	Analysis of Medicinals	81	Antiepileptic Drugs1501
30	Analysis of Medicinals	82	Psychopharmacologic Agents
31	Biological Testing	83	Analgesic, Antipyretic, and Anti-Inflammatory Drugs 1524
32	Clinical Analysis565	84	Histamine and Antihistaminic Drugs
33	Chromatography	85	Central Nervous System Stimulants
	Instrumental Methods of Analysis		
	672	86	Antineoplastic Drugs 1556
34 35	Dissolution	86 87	
35		87	Immunoactive Drugs
35	Pharmaceutical Manufacturing	87 88	Immunoactive Drugs
85 art 5	Pharmaceutical Manufacturing	87 88 89	Immunoactive Drugs     1588       Parasiticides     1599       Immunizing Agents and Allergenic Extracts     1600
85 <b>art 5</b> 6	Pharmaceutical Manufacturing Separation	87 88 89 90	Immunoactive Drugs1588Parasiticides1599Immunizing Agents and Allergenic Extracts1600Anti-Infectives1620
85 art 5 6 7	Pharmaceutical Manufacturing  Separation	87 88 89 90 91	Immunoactive Drugs
85 art 5 6 7 8	Pharmaceutical Manufacturing  Separation	87 88 89 90 91	Immunoactive Drugs1588Parasiticides1599Immunizing Agents and Allergenic Extracts1600Anti-Infectives1620Enzymes168Nutrients and Associated Substances168
85 <b>art 5</b> 6 7 8	Pharmaceutical Manufacturing  Separation	87 88 89 90 91	Immunoactive Drugs1588Parasiticides1599Immunizing Agents and Allergenic Extracts1600Anti-Infectives1620Enzymes168Nutrients and Associated Substances168
art 5 6 7 8 9	Pharmaceutical ManufacturingSeparation.691Powders.702Property-Based Drug Design and Preformulation.720Solutions, Emulsions, Suspensions, and Extracts.745Sterilization.776	87 88 89 90 91 92 93	Immunoactive Drugs1588Parasiticides1599Immunizing Agents and Allergenic Extracts1600Anti-Infectives1620Enzymes168Nutrients and Associated Substances168Pesticides171
art 5 6 7 8 9	Pharmaceutical ManufacturingSeparation691Powders702Property-Based Drug Design and Preformulation720Solutions, Emulsions, Suspensions, and Extracts745Sterilization776Parenteral Preparations802	87 88 89 90 91	Immunoactive Drugs1588Parasiticides1599Immunizing Agents and Allergenic Extracts1600Anti-Infectives1620Enzymes168Nutrients and Associated Substances168
85 art 5 6 7 8 9 0	Pharmaceutical ManufacturingSeparation691Powders702Property-Based Drug Design and Preformulation720Solutions, Emulsions, Suspensions, and Extracts745Sterilization776Parenteral Preparations802Intravenous Admixtures837	87 88 89 90 91 92 93	Immunoactive Drugs 1588 Parasiticides 1599 Immunizing Agents and Allergenic Extracts 1600 Anti-Infectives 1620 Enzymes 1680 Nutrients and Associated Substances 1680 Pesticides 1711  Pharmacy Practice
5 art 5	Pharmaceutical ManufacturingSeparation691Powders702Property-Based Drug Design and Preformulation720Solutions, Emulsions, Suspensions, and Extracts745Sterilization776Parenteral Preparations802Intravenous Admixtures837Ophthalmic Preparations850	87 88 89 90 91 92 93 Part 8	Immunoactive Drugs
5	Pharmaceutical ManufacturingSeparation691Powders702Property-Based Drug Design and Preformulation720Solutions, Emulsions, Suspensions, and Extracts745Sterilization776Parenteral Preparations802Intravenous Admixtures837Ophthalmic Preparations850Medicated Topicals871	87 88 89 90 91 92 93 <b>Part 8</b>	Immunoactive Drugs
5 6 7 3	Pharmaceutical ManufacturingSeparation691Powders702Property-Based Drug Design and Preformulation720Solutions, Emulsions, Suspensions, and Extracts745Sterilization776Parenteral Preparations802Intravenous Admixtures837Ophthalmic Preparations850Medicated Topicals871Oral Solid Dosage Forms889	87 88 89 90 91 92 93 <b>Part 8</b>	Immunoactive Drugs
6 7 8 9	Pharmaceutical ManufacturingSeparation691Powders702Property-Based Drug Design and Preformulation720Solutions, Emulsions, Suspensions, and Extracts745Sterilization776Parenteral Preparations802Intravenous Admixtures837Ophthalmic Preparations850Medicated Topicals871Oral Solid Dosage Forms889Coating of Pharmaceutical Dosage Forms929	87 88 89 90 91 92 93 <b>Part 8</b> 94 95 96	Immunoactive Drugs
6 7 8 9	Pharmaceutical ManufacturingSeparation691Powders702Property-Based Drug Design and Preformulation720Solutions, Emulsions, Suspensions, and Extracts745Sterilization776Parenteral Preparations802Intravenous Admixtures837Ophthalmic Preparations850Medicated Topicals871Oral Solid Dosage Forms889Coating of Pharmaceutical Dosage Forms929	87 88 89 90 91 92 93 <b>Part 8</b>	Immunoactive Drugs
85 66 7 8 9 0	Pharmaceutical ManufacturingSeparation691Powders702Property-Based Drug Design and Preformulation720Solutions, Emulsions, Suspensions, and Extracts745Sterilization776Parenteral Preparations802Intravenous Admixtures837Ophthalmic Preparations850Medicated Topicals871Oral Solid Dosage Forms889	87 88 89 90 91 92 93 <b>Part 8</b> 94 95 96	



xxi

xxii	CONTENTS		
100 101 102	Professional Communications	117 118 119	Documenting, Billing, and Reimbursement for Pharmaceutical Care Services
103 104 105 106 107 108 109 110	Poison Control	120 121 122 123 124	C Patient Care  Specialization in Pharmacy Practice
111 112 113 114 115	B Social, Behavioral, Economic, and Administrative Sciences  Laws Governing Pharmacy Practice . 2055 Pharmacoeconomics . 2070 Community Pharmacy Economics and Management . 2082 Product Recalls and Withdrawals . 2098 Marketing Pharmaceutical Care Services . 2107	125 126 127 128 129 130 131 132 133	Diagnostic Self-Care



Parenteral (Gk, para enteron, beside the intestine) dosage forms differ from all other drug dosage forms because they are injected directly into body tissue through the primary protective system of the human body, the skin, and mucous membranes. They must be exceptionally pure and free from physical, chemical, and biological contaminants. These requirements place a heavy responsibility on the pharmaceutical industry to practice current good manufacturing practices (cGMPs) in the manufacture of parenteral dosage forms and upon pharmacists and other health care professionals to practice good aseptic practices (GAPs) in dispensing them for administration to patients.

Certain pharmaceutical agents, particularly peptides, proteins, and many chemotherapeutic agents, can only be given parenterally because they are inactivated in the gastrointestinal tract when given by mouth. Parenterally administered drugs are relatively unstable and generally high potent drugs that require strict control of their administration to the patient. Because of the advent of biotechnology, parenteral products have grown in number and usage around the world.

This chapter will focus on the unique characteristics of parenteral dosage forms and the basic principles for formulating, packaging, manufacturing, and controlling the quality of these unique products. The references and bibliography at the end of this chapter contain the most up-to-date texts, book chapters, and review papers on parenteral product formulation, manufacture, and quality control.

### **OVERVIEW OF UNIQUE** CHARACTERISTICS OF PARENTERAL DOSAGE FORMS

Parenteral products are unique from any other type of pharmaceutical dosage form for the following reasons:

- All products must be sterile.
- All products must be free from pyrogenic (endotoxin) contamina-
- Injectable solutions must be free from visible particulate matter. This includes reconstituted sterile powders.
- · Products should be isotonic although strictness of isotonicity depends on the route of administration. Products to be administered into the cerebrospinal fluid must be isotonic. Ophthalmic products, while not parenteral, also must be isotonic. Products to be administered by bolus injection by routes other than intravenous (IV) essentially should be isotonic or at least very close to isotonicity. IV infusions must be isotonic.

The author recognizes the long time contributions of Dr. Kenneth Avis. Dr. Avis died in January 1999. Dr. Avis authored this chapter in Remington since 1965. To honor his memory, the author has maintained most of his organization of this chapter with new material and revised information added where • All products must be stable (not only chemically and physically by All products must be stated. All products must be stated with the products all other dosage forms, but also "stable" microbiologically, ie, stall all other dosage forms, but also "stable" microbiologically, ie, stall all other dosage forms, but also "stable" microbiologically ie, stall all other dosage forms, but also "stable" microbiologically ie, stall other dosage forms, but also "stable" microbiologically ie, stall other dosage forms, but also "stable" microbiologically ie, stall other dosage forms, but also "stable" microbiologically ie, stall other dosage forms, but also "stable" microbiologically ie, stall other dosage forms, but also "stable" microbiologically ie, stall other dosage forms, but also "stable" microbiologically ie, stall other dosage forms, but also "stable" microbiologically ie, stall other dosage forms, but also "stable" microbiologically ie, stall other dosage forms, but also "stable" microbiologically ie, stall other dosage forms, but also "stable" microbiologically ie, stall other dosage forms, but also "stable" microbiologically ie, stall other dosage forms, but also "stable" microbiologically ie, stall other dosage for microbiological in the microbiol all other dosage forms, but also disible particulate contamination ity, freedom from pyrogenic and visible particulate contamination ity, freedom from pyrogenic and the shelflife of the most benefit in the shelflife of the shelflife of the shelflife of the shelflife of must be maintained throughout the shelflife of the product must be maintained through the mount becompatible (if applicable) with IV diluents, de products must be compatible (if applicable) with IV diluents, de products co-administration be ily iou prus Fi (e m st

CE

5

livery systems, and other drug products co-administered.

# FORMULATION PRINCIPLES

Parenteral drugs are formulated as solutions, suspensions emulsions, liposomes, microspheres, nanosystems, and por. ders to be reconstituted as solutions. This section will describe the components that are commonly used in parenteral formulations focusing on solutions and freeze-dried products. General guidance also will be provided on appropriate selection of the finished sterile dosage form and initial approaches used to develop the optimal parenteral formulation.

#### VEHICLES

WATER—Since most liquid injections are quite dilute, the component present in the highest proportion is the vehicle. The vehicle of greatest importance for parenteral products is water. Water of suitable quality for compounding and rinsing product contact surfaces may be prepared either by distillation or by reverse osmosis, to meet United States Pharmacopeia (USP) specifications for Water for Injection (WFI). Only by these two methods is it possible to separate adequately various liquid. gas, and solid contaminating substances from water. These two methods for preparation of WFI and specifications for WFI are discussed later in this chapter. With the possible exception of freeze-drying, there is no unit operation more important and none more costly to install and operate than the one for the preparation of WFI.

WATER-MISCIBLE VEHICLES—A number of solvents that are miscible with water have been used as a portion of the vehicle in the formulation of parenterals. These solvents are used primarily to solubilize certain drugs in an aqueous vehicle and to reduce hydrolysis. The most important solvents in this group are ethyl alcohol, liquid polyethylene glycol, and propier lene glycol. Ethyl alcohol is used particularly in the preparation of solutions of of solutions of cardiac glycosides and the glycols in solutions of barbiturates barbiturates, certain alkaloids, and certain antibiotics. preparations usually are given intramuscularly. There are intations with the itations with the amount of these co-solvents that can be stimulated because the state of these co-solvents and can be stimulated because the state of the state ministered because of toxicity concerns, greater potential hemolysis, and potential an hemolysis, and potential for drug precipitation at the site of injection. Formulation jection. Formulation scientists needing to use one or more these solvents must these solvents must consult the literature (eg, reference 2) solvents toxicologists to account the literature (eg, reference 2) solvents toxicologists to ascertain the maximum amount of co-solvents

802



# DOCKET

# Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

# **Real-Time Litigation Alerts**



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## **Advanced Docket Research**



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

# **Analytics At Your Fingertips**



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

#### API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

#### **LAW FIRMS**

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

#### **FINANCIAL INSTITUTIONS**

Litigation and bankruptcy checks for companies and debtors.

### **E-DISCOVERY AND LEGAL VENDORS**

Sync your system to PACER to automate legal marketing.

